Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 8 Oct 2008 |
| Genmab Reports Results of Portfolio Review | 8 Oct 2008 |
| Grant of Warrants to Board Members, Management and Employees in Genmab A/S | 8 Oct 2008 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 8 Oct 2008 |
| Major Shareholder Announcement | 2 Oct 2008 |